FMP
Abeona Therapeutics Inc.
ABEO
NASDAQ
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
5.7 USD
0.07 (1.23%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Vishwas Seshadri M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biophar...
CIK
0000318306
ISIN
US00289Y2063
CUSIP
00289Y107
Address
1330 Avenue of the Americas
Phone
646 813 4701
Country
US
Employee
84
IPO Date
Sep 19, 1980
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ABEO Financial Summary
CIK
0000318306
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00289Y107
ISIN
US00289Y2063
Country
US
Price
5.7
Beta
1.5
Volume Avg.
268.87k
Market Cap
247.78M
Shares
-
52-Week
3.05-9.01
DCF
-0.69
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.78
P/B
-
Website
https://www.abeonatherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ABEO News
It looks like there's no news available.
